Infections, bacterial resistance, and antimicrobial stewardship: The emerging role of hospitalists

Journal of Hospital Medicine

Volumn 7, Issue SUPPL. 1, 2012, Pages

  Rosenberg, David J ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE COURSE; DRUG USE; ENTEROBACTER; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HEALTH CARE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH PROGRAM; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MEDICAL PRACTICE; MEDICAL STAFF; MORTALITY; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; REVIEW; UNITED STATES; BACTERIAL INFECTION; COMMUNICABLE DISEASE; CROSS INFECTION; DRUG EFFECT; PHYSICIAN ATTITUDE; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HOSPITALISTS; HUMANS; PHYSICIAN'S ROLE;

EID: 84855332485     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.978     Document Type: Review

References (98)

1. Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007; 122: 160-166.
2. Pearson A. Historical and changing epidemiology of healthcare-associated infections. J Hosp Infect. 2009; 73: 296-304.
3. Smyth ET, McIlvenny G, Enstone JE, et al. Four country healthcare associated infection prevalence survey 2006: overview of the results. J Hosp Infect. 2008; 69: 230-248.
4. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008; 29: 996-1011.
5. Glupczynski Y, Bogaerts P, Deplano A, et al. Detection and characterization of class A extended-spectrum-beta-lactamase-producing Pseudomonas aeruginosa isolates in Belgian hospitals. J Antimicrob Chemother. 2010; 65: 866-871.
6. Morgan DJ, Weisenberg SA, Augenbraun MH, et al. Multidrug-resistant Acinetobacter baumannii in New York City-10 years into the epidemic. Infect Control Hosp Epidemiol. 2009; 30: 196-197.
7. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 2008;13(47):pii=19045. Available at: Accessed on March 29, 2011.
8. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010; 340: c2096.
9. Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med. 2006; 119: 526.e519-526.e525.
10. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2006; 27: 893-900.
11. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005; 41: 435-440.
12. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003; 289: 885-888.
13. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009; 53: 1983-1986.
14. Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis. 2004; 39: 497-503.
15. Regal RE, DePestel DD, VandenBussche HL. The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to beta-lactams in a large teaching hospital. Pharmacotherapy. 2003; 23: 618-624.
16. Rogues AM, Dumartin C, Amadeo B, et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol. 2007; 28: 1389-1395.
17. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med. 1997; 337: 441-446.
18. Dellit TH, Owens RC, McGowan JEJr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44: 159-177.
19. Shlaes DM, Gerding DN, John JFJr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997; 25: 584-599.
20. Ohl CA, Luther VP. Antimicrobial stewardship for inpatient facilities. J Hosp Med. 2011; 6( suppl 1): S4-S15.
21. Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect Dis Clin North Am. 2011; 25: 245-260.
22. Peterson LR. Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis. 2009; 49: 992-993.
23. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008; 197: 1079-1081.
24. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008; 6: 751-763.
25. Sipahi OR. Economics of antibiotic resistance. Expert Rev Anti Infect Ther. 2008; 6: 523-539.
26. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2008; 52: 570-573.
27. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother. 2005; 49: 4423-4424.
28. Akpaka PE, Swanston WH, Ihemere HN, et al. Emergence of KPC-producing Pseudomonas aeruginosa in Trinidad and Tobago. J Clin Microbiol. 2009; 47: 2670-2671.
29. Navon-Venezia S, Leavitt A, Schwaber MJ, et al. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother. 2009; 53: 818-820.
30. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009; 9: 228-236.
31. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006; 355: 666-674.
32. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007; 298: 1763-1771.
33. Jenkins TC, McCollister BD, Sharma R, et al. Epidemiology of healthcare-associated bloodstream infection caused by USA300 strains of methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Infect Control Hosp Epidemiol. 2009; 30: 233-241.
34. Klein E, Smith DL, Laxminarayan R. Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006. Emerg Infect Dis. 2009; 15: 1925-1930.
35. Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis. 2007; 13: 236-242.
36. Park SH, Park C, Yoo JH, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated bloodstream infections in Korea. Infect Control Hosp Epidemiol. 2009; 30: 146-155.
37. Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis. 2008; 46: 787-794.
38. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated bloodstream infections. Clin Infect Dis. 2006; 42: 647-656.
39. Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009; 23: 727-743.
40. Vaishnavi C. Established and potential risk factors for Clostridum difficile infection. Indian J Med Microbiol. 2009; 27: 289-300.
41. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg. 2007; 142: 624-631.
42. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis. 2008; 14: 929-931.
43. Zilberberg MD, Shorr AF, Kollef MH. Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005. Pediatr Infect Dis J. 2008; 27: 1111-1113.
44. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002; 34: 346-353.
45. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31: 431-455.
46. Hsu J, Abad C, Dinh M, Safdar N. Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol. 2010; 105: 2327-2340.
47. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353: 2442-2449.
48. Salgado CD, Mauldin PD, Fogle PJ, Bosso JA. Analysis of an outbreak of Clostridium difficile infection controlled with enhanced infection control measures. Am J Infect Control. 2009; 37: 458-464.
49. Weiss K, Boisvert A, Chagnon M, et al. Multipronged intervention strategy to control an outbreak of Clostridium difficile infection (CDI) and its impact on the rates of CDI from 2002 to 2007. Infect Control Hosp Epidemiol. 2009; 30: 156-162.
50. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med. 1998; 128: 989-995.
51. Fowler S, Webber A, Cooper BS, et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother. 2007; 59: 990-995.
52. Khan R, Cheesbrough J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infect. 2003; 54: 104-108.
53. Ludlam H, Brown N, Sule O, Redpath C, Coni N, Owen G. An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea. Age Ageing. 1999; 28: 578-580.
54. O'Connor KA, Kingston M, O'Donovan M, Cryan B, Twomey C, O'Mahony D. Antibiotic prescribing policy and Clostridium difficile diarrhoea. Q J Med. 2004; 97: 423-429.
55. Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis. 2007; 45( suppl 2): S112-S121.
56. Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. 2009; 9: 417-422.
57. Scott RD II. The Direct Medical Costs of Healthcare-Associated Infections in US Hospitals and the Benefits of Prevention. Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention. Polock DA, Stone PW, eds. London, UK: Economist; 2009.
58. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006; 50: 43-48.
59. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005; 26: 166-174.
60. Kwon KT, Oh WS, Song JH, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother. 2007; 59: 525-530.
61. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001; 32: 1162-1171.
62. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2005; 52: 113-122.
63. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006; 50: 1257-1262.
64. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med. 2001; 135: 484-492.
65. Wilson SJ, Knipe CJ, Zieger MJ, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control. 2004; 32: 342-344.
66. Young LS, Sabel AL, Price CS. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2007; 28: 1247-1254.
67. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006; 42( suppl 2): S82-S89.
68. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009; 49: 1175-1184.
69. The Joint Commission. About The Joint Commission. Available at: Accessed March 29, 2011.
70. The Joint Commission. Accreditation Program: Hospital. National Patient Safety Goals. Effective January 1, 2011. Available at: Accessed January 24, 2011.
71. Deficit Reduction Act. Sec. 5001. Hospital Quality Improvement. Available at: Accessed March 29, 2011.
72. Centers for Disease Control and Prevention (CDC). Get Smart: Know When Antibiotics Work. Available at: Accessed March 30, 2011.
73. Centers for Disease Control and Prevention (CDC). National Ambulatory Medical Care Survey. Available at: Accessed March 30, 2011.
74. Centers for Disease Control and Prevention (CDC). About Healthy People 2010. Available at: Accessed March 30, 2011.
75. Centers for Disease Control and Prevention (CDC). DATA2010...the Healthy People 2010 Database. Available at: by searching for antibiotic. Accessed March 30, 2011.
76. Centers for Disease Control and Prevention (CDC). Get Smart for Healthcare. Available at: Accessed March 29, 2011.
77. The Institute for Healthcare Improvement (IHI). About IHI. Available at: Accessed March 29, 2011.
78. Centers for Disease Control and Prevention (CDC). Get Smart for Healthcare: All Clinicians Should.... Available at: Accessed May 3, 2011.
79. United States Department of Health & Human Services (HHS). HHS Action Plan to Prevent Healthcare-Associated Infections. Available at: Accessed March 29, 2011.
80. Centers for Disease Control and Prevention (CDC). Public Health Action Plan to Combat Antimicrobial Resistance. Executive summary. Available at: Accessed March 31, 2011.
81. Centers for Disease Control and Prevention (CDC). Draft Action Plan-A Public Health Action Plan to Combat Antimicrobial Resistance 2010. Available at: or Accessed March 31, 2011.
82. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev. 2005; 18: 638-656.
83. Owens RCJr. Antimicrobial stewardship: application in the intensive care unit. Infect Dis Clin North Am. 2009; 23: 683-702.
84. Drew RH, Kawamoto K, Adams MB. Information technology for optimizing the management of infectious diseases. Am J Health Syst Pharm. 2006; 63: 957-965.
85. Woeltje KF, Lautenbach E. Informatics and epidemiology in infection control. Infect Dis Clin North Am. 2011; 25: 261-270.
86. Fraser GL, Stogsdill P, Dickens JDJr, Wennberg DE, Smith RPJr, Prato BS. Antibiotic optimization. An evaluation of patient safety and economic outcomes. Arch Intern Med. 1997; 157: 1689-1694.
87. Gums JG, Yancey RW Jr, Hamilton CA, Kubilis PS. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy. 1999; 19: 1369-1377.
88. Centers for Disease Control and Prevention (CDC). Get Smart for Healthcare: Impact of Antibiotic Stewardship Program Interventions on Costs. Available at: Accessed May 3, 2011.
89. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003; 24: 699-706.
90. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000; 162: 505-511.
91. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997; 25: 230-239.
92. Kuo YF, Sharma G, Freeman JL, Goodwin JS. Growth in the care of older patients by hospitalists in the United States. N Engl J Med. 2009; 360: 1102-1112.
93. Society of Hospital Medicine (SHM). Information About SHM and Hospitalists. Available at: Accessed April 1, 2011.
94. Society of Hospital Medicine (SHM). New Study Finds Over Half of US Hospitals Utilize Hospitalists. Available at: Accessed May 3, 2011.
95. Society of Hospital Medicine (SHM). SHM Fact Sheet: About Hospital Medicine. Available at: Accessed April 3, 2011.
96. Society of Hospital Medicine (SHM). Definition of a Hospitalist and Hospital Medicine. Available at: Accessed April 3, 2011.
97. Kurtin P, Stucky E. Standardize to excellence: improving the quality and safety of care with clinical pathways. Pediatr Clin North Am. 2009; 56: 893-904.
98. Srinivasan A. Engaging hospitalists in antimicrobial stewardship: the CDC perspective. J Hosp Med. 2011; 6( suppl 1): S31-S33.